BioSpace

RevMed pads Rasonque’s first-line survival advantage in pancreatic cancer with early data

The new data could help boost Revolution Medicines beyond the currently estimated $14.5 billion in peak sales for the recently approved RAS(ON) inhibitor, Truist Securities predicts.

By BioSpace

1 min read
RevMed pads Rasonque’s first-line survival advantage in pancreatic cancer with early data
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights